Overview

Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Status:
Recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects of nivolumab and ipilimumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Phase:

Phase 1

Details

Lead Sponsor:

Sabine Mueller, MD, PhD

Collaborators:

Bristol-Myers Squibb
Pacific Pediatric Neuro-Oncology Consortium

Treatments:

Ipilimumab
Nivolumab